IGNITE is an accelerator program for medtech entrepreneurs, designed and supported by the medtech industry. Through three-months of intensive programming access to on-demand content and one-on-one work with an industry mentor, the program accelerates the founder’s journey during the most vulnerable stage of their company’s lifecycle.


IGNITE was originally launched in 2004 and ran for 10 years, producing a number of notable alumni, including Jim Biggins, founder and CEO of Access Vascular and John McDonough, founder, president and CEO of T2Biosystems.

Relaunched in the spring of 2019, IGNITE is supported in part by a grant from the Massachusetts Life Sciences Center (MLSC) and program sponsors.

IGNITE Benefits

  • One-on-one expert mentoring
  • Master classes from medtech experts
  • Personalized pitch support & feedback
  • Access to senior industry leaders
  • Exclusive invite-only gatherings
  • Discounts to medtech events
  • Publicity and awareness


The IGNITE Program curriculum is a three-month (September – November), intensive, hybrid program for medtech startups. Through work with an expert panel of advisors and investors, and individual guidance from industry mentors, IGNITE cohort members are afforded the knowledge, tools and connections to move along their start-up journey. All cohort members also have 24/7 access to an on-demand library of curriculum designed by legal, financial, business, entrepreneurial and medtech experts they can consume at their own pace.

Who We Are Looking For

The IGNITE Program best serves early stage medtech founders. This typically means:

We look for companies who are at the pre-seed or seed round stage (i.e., companies who have raised 2M or less in equity financing) 

The company has plans for an FDA regulated medical device. Regulatory pathways do not need to be confirmed for acceptance

Pharma companies are not a good fit for this program, but drug delivery companies are

Companies have the ability to be in Boston, MA during a portion of the hybrid program